<?xml version="1.0" encoding="UTF-8"?>
<p id="p0205">According to Guan et al.,
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> 14.5% of severe patients (25/173) received invasive mechanical ventilation and 32.4% (56/173) received noninvasive mechanical ventilation. If standard oxygen therapy fails, Chinese guidelines recommend a trial of HFNC or noninvasive ventilation, but WHO guidelines recommend escalating to invasive mechanical ventilation.
 <xref rid="bib21" ref-type="bibr">
  <sup>21</sup>
 </xref> It is generally accepted that timely use of invasive mechanical ventilation is an important component of the treatment of severe respiratory failure and acute respiratory distress syndrome (ARDS).
 <xref rid="bib32" ref-type="bibr">
  <sup>32</sup>
 </xref> Based on a Chinese expert consensus,
 <xref rid="bib33" ref-type="bibr">
  <sup>33</sup>
 </xref> it is recommended that invasive mechanical ventilation be the first choice for moderate or severe ARDS patients (PaO
 <sub>2</sub>/FiO
 <sub>2</sub> ≤ 150 mm Hg)
 <xref rid="bib34" ref-type="bibr">
  <sup>34</sup>
 </xref> or for patients after failure of HFNC and NIPPV. Lung-protective ventilation strategy, ie, low tidal volumes (6-8 mL/kg of predicted body weight) and low inspiratory pressures (platform pressure &lt; 30 cm H
 <sub>2</sub>O) should be incorporated to prevent ventilator-related lung injury.
 <xref rid="bib32" ref-type="bibr">
  <sup>32</sup>
 </xref>
</p>
